EGFR Inhibitor TY-9591 clinical trials
Also written TY-9591.
How each study uses EGFR Inhibitor TY-9591 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the EGFR Inhibitor TY-9591 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
TYK Medicines, Inc (7)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses EGFR Inhibitor TY-9591 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingPhase 2TYK Medicines, IncNCT05948813Written as TY-9591
- A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNot yet recruitingPhase 2TYK Medicines, IncNCT06672068Written as TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingPhase 3TYK Medicines, IncNCT05382728Written as TY-9591
- Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationCompletedPhase 2TYK Medicines, IncNCT05146219Written as TY-9591 Tablets
- [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese SubjectsCompletedPhase 1TYK Medicines, IncNCT05871905Written as TY-9591
- A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive MutationCompletedPhase 1TYK Medicines, IncNCT04204473Written as TY-9591(10mg,40mg) qd. po
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompletedPhase 1TYK Medicines, IncNCT04798638Written as TY-9591 Tablets under Fasted Condition - Arm1